E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Male or female patients with a clinical diagnosis of either Discoid Lupus Erythmatosus or Systemic Lupus Erythmatosus and at least one newly developed, sharply demarcated DLE lesion. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025138 |
E.1.2 | Term | Lupus erythematosus discoides |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare the treatment effect of ASF-1096 cream 0.5% to ASF-1096 Cream Placebo on a newly developed DLE lesion after 8 weeks of twice daily, topical treatment. |
|
E.2.2 | Secondary objectives of the trial |
To compare the treatment effect of ASF-1096 cream 0.5% to ASF-1096 cream placebo with regard to the response/rating on/of: •Erythema •Scaling/hypertrophy •Dyspigmentation •Scarring/Atrophy/Panniculitis •Induration •Pain •Itching •Lesion area •General improvement assessed by the investigator •Global improvement assessed by the patient after 2, 4, 6 and 8 weeks of treatment. To compare and describe the safety profile in the ASF-1096 cream 0.5% and ASF-1096 cream placebo groups.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
All of the following criteria have to be met for inclusion of a patient in the study: •Patients of any gender aged from 18 to 70 years; •A clinical diagnosis of either DLE or SLE; •At least one newly developed, sharply demarcated DLE lesion (target lesion) with erythema score > 1 and scaling score > 1; •Histological results from biopsy confirming the diagnosis will be obtained at the beginning of the study, in case histological results confirming the diagnosis are available a new biopsy is not needed; •The physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study; •Sexually active females of childbearing potential should either be surgically sterile (hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen for at least 12 weeks prior to the study, during the study and one month after the end of the study; systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intrauterine device (IUD), condom with intravaginal spermicide; •Willing and able to comply to the study procedures; •Prepared to grant authorised persons access to the medical records; •Signed informed consent.
|
|
E.4 | Principal exclusion criteria |
Patients will not be included in the study when one or more of the following conditions are met: •Active skin disease other then DLE or another progressive or serious disease that interferes with the study outcome; •Scarring at the target lesion; •Keratonisation of treated lesion; •Concomitant, or within four weeks prior to dosing, treatment with corticosteroids (local or systemic), anti-malarials, retinoids or thalidomide; •Systemic treatment of SLE; •Concomitant, or within four weeks prior to dosing, treatment with medicinal products containing salbutamol (local or systemic); •Symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study; •Participation in another clinical trial, including the four week period preceding the study; •Known allergic reactions to components of the study preparations; •Pregnancy (according to pregnancy test) or nursing.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint for this study is the efficacy of ASF-1096 cream 0.5% compared to the ASF-1096 cream placebo using the area under the curve (AUC) of the local CLASI score. For analysis of the primary end point the null hypothesis H0: The mean AUCs of the local CLASI score in the groups treated with ASF-1096 cream 0.5% and the ASF-1096 cream placebo are the same. will be tested versus the alternative hypothesis H1: The mean AUCs of the local CLASI score in the groups treated with ASF-1096 cream 0.5% and the ASF-1096 cream placebo are not the same.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is the last visit of the last subject undergoing the trial. In the case of premature termination for any reason in a patient, the patient will be asked to do the End of Trial visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 6 |